Key result
Novel Danshensu derivative D006 attenuates doxorubicin cardiotoxicity while enhancing breast cancer cell apoptosis preclinically.
Why the study?
Doxorubicin use is limited by cardiotoxicity, and a novel Danshensu derivative with improved stability and activity was synthesized to investigate protective and chemosensitizing effects.
Does D006 prevent doxorubicin-induced cardiotoxicity and improve chemotherapeutic efficacy in preclinical models?
Population
H9c2 cells, human breast tumor MCF-7 cells, and zebrafish model
Comparison
D006 plus Doxorubicin vs Doxorubicin alone, parental compounds, or their combination
Design
Preclinical in vitro and in vivo study
Authors
Loading...
Hypothesis-generating for dual cardioprotection and chemosensitization; leaves open translation to clinical doxorubicin regimens.
Does D006 prevent doxorubicin-induced cardiotoxicity and improve chemotherapeutic efficacy in preclinical models?
D006, a novel Danshensu derivative, shows promise in preclinical models for preventing doxorubicin-induced cardiotoxicity while enhancing its anti-cancer efficacy.
Wang et al. (2015) studied Doxorubicin-induced cardiotoxicity and breast cancer. D006 (novel Danshensu derivative) vs. Doxorubicin alone, DSS, or parental compounds was evaluated on Cardiotoxicity and antitumor activity. The novel Danshensu derivative D006 protected against doxorubicin-induced cardiotoxicity in H9c2 cells and zebrafish while enhancing doxorubicin-induced apoptosis in human breast tumor MCF-7 cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: